What is the appropriate evaluation and management for a patient with elevated liver enzymes?

Evaluation and Management of Elevated Liver Enzymes

Begin with a detailed clinical assessment focusing on alcohol intake (quantified in units/week), medication history (including over-the-counter drugs and supplements), metabolic risk factors (BMI, diabetes, dyslipidemia, hypertension), and physical examination for signs of chronic liver disease or hepatic decompensation. 1

Initial Clinical Assessment

The evaluation must be tailored to the specific pattern and degree of enzyme elevation, as this determines both urgency and diagnostic approach:

Degree of Elevation Determines Urgency

• Mild elevations (<5 times upper limit of normal): Proceed with systematic outpatient evaluation 1, 2
• Marked elevations (>5 times normal): Require immediate, expeditious evaluation as they indicate severe hepatic injury 1, 3
• Chronic elevations (≥6 months): Warrant additional serologic and radiologic evaluations, potentially including liver biopsy 1

Pattern Recognition

Determine whether the pattern is hepatocellular (ALT/AST predominant) versus cholestatic (alkaline phosphatase/bilirubin predominant), as this fundamentally changes the diagnostic pathway. 1, 4

• For conjugated hyperbilirubinemia with elevated alkaline phosphatase: Exclude biliary obstruction first 1
• For unconjugated hyperbilirubinemia: Evaluate for Gilbert's syndrome, hemolysis, and medication-induced causes 1

First-Line Serologic Testing

Order the following initial panel to identify common hepatic diseases before pursuing extensive testing: 1, 2, 5

• Viral hepatitis: Hepatitis B surface antigen (HBsAg), Hepatitis B core antibody-IgM (HBcIgM), Hepatitis C antibody (consider HCV-RNA if positive) 1
• Metabolic assessment: Fasting glucose or HbA1c, lipid profile, BMI calculation 1, 2, 5
• Iron studies: Serum iron, total iron-binding capacity, ferritin (for hereditary hemochromatosis) 2, 5
• Complete blood count with platelets 2, 5
• Serum albumin and INR (to assess synthetic function) 1, 2

Focused vs. Extensive Testing Strategy

Use focused testing when clinical clues suggest specific diagnoses, as this approach is more cost-effective and generates fewer false-positives when pre-test probability is considered. 6

• Focused testing becomes superior when prevalence of alcoholic liver disease exceeds 51.1%, NAFLD exceeds 53.0%, or drug-induced liver injury exceeds 13.0% 6
• Extensive testing (ordering all tests simultaneously) is only appropriate when there are absolutely no clinical clues 6

Risk Stratification by Common Causes

NAFLD/MASLD (Most Common Cause)

For patients with metabolic risk factors (obesity, T2DM, dyslipidemia, hypertension), proceed directly to fibrosis risk stratification using non-invasive tests. 1, 7

First-line fibrosis assessment: 1

• Calculate FIB-4 or NAFLD Fibrosis Score (NFS)
• Low-risk cutoffs: FIB-4 <1.3, NFS ≤-1.455
• For patients >65 years: Use higher cutoffs (FIB-4 <2.0, NFS <-0.12) 1

Second-line fibrosis assessment (if first-line indeterminate): 1

• Enhanced Liver Fibrosis (ELF) score
• FibroScan/ARFI elastography
• VCTE thresholds: <8 kPa (low risk), 8-15 kPa (F2-F3), 15-20 kPa (possible cirrhosis), >20 kPa (cirrhosis) 8, 7

Alcohol-Related Liver Disease

Quantify alcohol consumption precisely using AUDIT-C screening, followed by full 10-item AUDIT if positive. 1

• AUDIT score >19: Refer to alcohol dependency services 1
• Harmful drinkers (≥35 units/week for women, ≥50 units/week for men): Perform FibroScan/ARFI elastography for risk stratification 1
• FibroScan >16 kPa or clinical features of cirrhosis/portal hypertension: Refer to secondary care 1

Critical caveat: Alcohol and obesity have synergistic effects—when BMI >35, the risk of liver disease doubles for any given alcohol intake 1

Drug-Induced Liver Injury

Review all medications, supplements, and herbal products systematically, as this is an uncommon but important reversible cause 2, 5

When to Refer to Hepatology

Refer patients to a hepatologist/gastroenterologist with liver expertise in the following scenarios: 1

• Abnormal liver tests with negative extended liver screen AND no NAFLD risk factors 1
• Evidence of advanced liver disease (features of cirrhosis, portal hypertension on imaging, or FibroScan >16 kPa) 1
• Chronic elevations (≥6 months) despite initial evaluation 1
• Severe liver chemistry abnormalities or evidence of hepatic decompensation (abnormal albumin, INR, or platelets) 1
• Suspected autoimmune liver disease (noting that autoantibodies may be negative in some cases) 1

Management Approach for MASLD

Lifestyle modification remains the cornerstone regardless of pharmacotherapy, including weight loss, dietary changes, physical exercise, and alcohol moderation. 7

Pharmacotherapy Considerations

For MASH with F2-F3 fibrosis (identified by NITs, not requiring biopsy): 8

• Semaglutide 2.4 mg/week subcutaneously (Wegovy®) received FDA accelerated approval in August 2025 for MASH with moderate to advanced fibrosis 8
• Achieved MASH resolution in 62.9% vs 34.3% placebo and ≥1 stage fibrosis reduction in 36.8% vs 22.4% placebo at 72 weeks 8

For non-cirrhotic MASH with significant fibrosis (stage ≥2): 7

• Consider resmetirom if locally approved, which demonstrated histological effectiveness on steatohepatitis and fibrosis 7

Incretin-based therapies (semaglutide, tirzepatide) should be used for T2DM or obesity management in MASLD patients when indicated 7

Monitoring Treatment Response

For patients on semaglutide, monitor for: 8

• Gastrointestinal side effects (nausea, diarrhea, constipation, vomiting)—generally mild and transient
• Rare serious risks: Acute kidney injury from dehydration, symptomatic gallbladder disease, pancreatitis, thyroid C-cell tumors, retinopathy progression, lean mass loss
• Hepatic panels only as clinically indicated (not routine, as hepatic safety profile is favorable) 8

Treatment response indicators at 72 weeks: 8

• ALT reduction >17 U/L or ≥20%
• CAP reduction ≥30%
• VCTE LSM reduction ≥30%
• MRE LSM reduction ≥20%
• ELF reduction ≥0.5

Key Pitfalls to Avoid

• Do not assume normal liver enzymes exclude advanced fibrosis or cirrhosis—liver disease develops silently, and enzymes may be normal even with progressive fibrosis 1
• Do not order liver biopsies routinely for MASLD staging—NITs are practical and sufficient for most patients 8, 7
• Do not overlook extrahepatic causes: Thyroid disorders, celiac disease, hemolysis, muscle disorders, and pregnancy-associated liver disease 2, 5
• Do not miss the synergy between alcohol and obesity when assessing risk 1
• Do not delay referral in patients with negative workup but persistent abnormalities—treatable conditions like autoimmune hepatitis may have normal autoantibodies and immunoglobulins 1